Outcomes

The reported outcomes for SS-31 (Elamipretide) span multiple therapeutic areas, though the evidence base is limited and primarily derived from preclinical studies with one small clinical trial.

Neurological Outcomes

In preclinical stroke models, SS-31 combination therapy demonstrated measurable neuroprotective effects, including targeting TREM2 pathways to reduce post-ischemic brain injury. For spinal cord injury, the compound showed preservation of mitochondrial bioenergetics and promotion of neural remodeling, though specific functional outcome measures were not detailed in the available abstracts.

In Parkinson's disease models, SS-31 modulated α-synuclein membrane binding and aggregation while restoring impaired mitochondrial function. For age-related cognitive decline, the compound provided protection against endothelial glycocalyx degradation and associated neuroinflammation in aged rats.

Cardiovascular and Muscle Performance

In heart failure with preserved ejection fraction (HFpEF) rat models, SS-31 improved skeletal muscle performance through targeting mitochondrial dysfunction. However, specific performance metrics and the magnitude of improvement were not quantified in the available evidence.

Respiratory Outcomes

For ozone-induced respiratory symptoms, SS-31 demonstrated protective mechanisms against airway hyperresponsiveness and mucus hypersecretion, though measurable clinical endpoints were not specified.

Clinical Trial Evidence

One completed Phase 1/2 clinical trial (NCT05168774) investigated SS-31 in Friedreich's ataxia, but outcome data from this study are not yet available in the provided literature.

Evidence Limitations

The strength of evidence is notably limited. Most reported outcomes derive from animal studies with publication dates in 2025-2026, suggesting very recent or potentially preliminary research. Quantitative outcome measures, effect sizes, and statistical significance data are largely absent from the available abstracts. The single completed clinical trial lacks published results, leaving human efficacy data unavailable.

This information is for research purposes only and does not constitute medical advice. Consult healthcare professionals for treatment decisions.

SS-31 (Elamipretide)

Member access required